Your browser doesn't support javascript.
loading
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Ferro, Matteo; Crocetto, Felice; Tataru, Sabin; Barone, Biagio; Dolce, Pasquale; Lucarelli, Giuseppe; Sonpavde, Guru; Musi, Gennaro; Antonelli, Alessandro; Veccia, Alessandro; Terracciano, Daniela; Busetto, Gian Maria; Del Giudice, Francesco; Marchioni, Michele; Schips, Luigi; Porpiglia, Francesco; Fiori, Cristian; Carrieri, Giuseppe; Lasorsa, Francesco; Verde, Antonio; Scafuri, Luca; Buonerba, Carlo; Di Lorenzo, Giuseppe.
Afiliação
  • Ferro M; Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: matteo.ferro@ieo.it.
  • Crocetto F; Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy.
  • Tataru S; Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Barone B; Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy.
  • Dolce P; Department of Public Health, Federico II University of Naples, Naples, Italy.
  • Lucarelli G; Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
  • Sonpavde G; Genitourinary Oncology and Phase I Section, AdventHealth Cancer Institute, Orlando, FL.
  • Musi G; Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Antonelli A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Veccia A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Terracciano D; Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy.
  • Busetto GM; Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
  • Del Giudice F; Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy.
  • Marchioni M; Department of Urology, University of Chieti, Chieti, Italy.
  • Schips L; Department of Urology, University of Chieti, Chieti, Italy.
  • Porpiglia F; School of Medicine, Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.
  • Fiori C; School of Medicine, Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy.
  • Carrieri G; Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
  • Lasorsa F; Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
  • Verde A; Department of Urology, University of Chieti, Chieti, Italy.
  • Scafuri L; Oncology Unit, Hospital "Andrea Tortora," ASL Salerno, Pagani, Italy; Associazione O.R.A., Somma Vesuviana, Italy.
  • Buonerba C; Oncology Unit, Hospital "Andrea Tortora," ASL Salerno, Pagani, Italy; Associazione O.R.A., Somma Vesuviana, Italy.
  • Di Lorenzo G; Oncology Unit, Hospital "Andrea Tortora," ASL Salerno, Pagani, Italy; Associazione O.R.A., Somma Vesuviana, Italy.
Clin Genitourin Cancer ; 21(5): 574-583, 2023 10.
Article em En | MEDLINE | ID: mdl-37419854
ABSTRACT

INTRODUCTION:

Several programmed death ligand-1 (PD1/L1) immune checkpoint inhibitors (ICIs) are approved in urothelial carcinoma (UC). PATIENTS AND

METHODS:

To address the need for predictors of the efficacy of ICIs in metastatic urothelial carcinoma (mUC), randomized controlled trials of PD1/L1 inhibitors alone or in combination with chemotherapy in this patient population were systematically reviewed, and differences in ICI-associated survival outcomes according to available baseline variables were quantitatively assessed.

RESULTS:

The quantitative analysis included 6524 patients with mUC. No visceral metastatic site (HR 0.67; 95% CI, 0.76-0.90) and high PDL-1 expression (HR 0.74; 95% CI, 0.640.87) were significantly associated with a reduced risk of death.

CONCLUSION:

Treatment with an ICI-containing regimen was associated with a reduced risk of death in mUC patients, which was associated with PDL-1 expression and metastatic site. Further research is warranted.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Idioma: En Ano de publicação: 2023 Tipo de documento: Article